Inogen (INGN) Cash from Financing Activities (2013 - 2026)
Inogen (INGN) posted quarterly Cash from Financing Activities of -$2.1 million for Q1 2026, down 108.86% year-over-year from $24.0 million in Q1 2025, and down 1035.29% quarter-over-quarter from -$187000.0 in Q4 2025.
Inogen (INGN) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Inogen (INGN) has reported Cash from Financing Activities for 14 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 108.86% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 107.91% YoY), while the FY2025 annual figure was $24.2 million, up 9025.28% from the prior year.
- Cash from Financing Activities declined to -$2.1 million in Q1 2026 per INGN's latest filing, from -$187000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $24.0 million in Q1 2025 and bottomed at -$2.1 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $1.5 million across 5 years, with a median of -$23500.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities slumped 1757.14% — and 2025, when it soared 8303.86%.
- Inogen's Cash from Financing Activities stood at -$112000.0 in 2022, then surged by 87.5% to -$14000.0 in 2023, then plunged by 1757.14% to -$260000.0 in 2024, then advanced by 28.08% to -$187000.0 in 2025, then slumped by 1035.29% to -$2.1 million in 2026.
- Business Quant data shows INGN's Cash from Financing Activities at -$2.1 million in Q1 2026, -$187000.0 in Q4 2025, and $418000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Inogen | 152.26 Mn | 46.72 Mn | 43.27 Mn | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.62 Mn |
| Jun 30, 2026 | -5.62 Mn |
| Mar 31, 2026 | -2.12 Mn |
| Mar 31, 2026 | -2.12 Mn |
| Dec 31, 2025 | -187,000.00 |
| Dec 31, 2025 | -187,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 23.95 Mn |
| Mar 31, 2025 | 23.95 Mn |
| Dec 31, 2024 | -260,000.00 |
| Dec 31, 2024 | -260,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Jun 30, 2024 | -201,000.00 |
| Mar 31, 2024 | 285,000.00 |
| Mar 31, 2024 | 285,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Dec 31, 2023 | -14,000.00 |